| Multiple Myeloma
Carvykti vs Abecma
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Carvykti vs Abecma with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAbecma has a higher rate of injection site reactions vs Carvykti based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Abecma but not Carvykti, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Carvykti
Abecma
At A Glance
IV infusion
Single infusion
BCMA-directed CAR-T cell therapy
IV infusion
Single infusion
BCMA-directed CAR-T cell therapy
Indications
- Multiple Myeloma
- Multiple Myeloma
Dosing
Multiple Myeloma 0.5-1.0x10^6 CAR-positive viable T cells/kg IV (max 1x10^8 cells) as a single infusion, administered 2-4 days after lymphodepleting chemotherapy (cyclophosphamide 300 mg/m^2 IV and fludarabine 30 mg/m^2 IV daily for 3 days); premedicate with acetaminophen and an H1-antihistamine 30-60 minutes prior to infusion.
Multiple Myeloma Lymphodepleting chemotherapy: cyclophosphamide 300 mg/m2 IV and fludarabine 30 mg/m2 IV for 3 days; administer ABECMA 300 to 510 x 10^6 CAR-positive T cells by IV infusion two days after completion of lymphodepleting chemotherapy; premedicate with acetaminophen and an H1-antihistamine approximately 30 to 60 minutes before infusion.
Contraindications
—
—
Adverse Reactions
Most common (>20%) Pyrexia, cytokine release syndrome, hypogammaglobulinemia, hypotension, musculoskeletal pain, fatigue, infections-pathogen unspecified, cough, chills, diarrhea, nausea, encephalopathy, decreased appetite, upper respiratory tract infection, headache, tachycardia, dizziness, dyspnea, edema, viral infections, coagulopathy, constipation, vomiting
Serious Pneumonia, cytokine release syndrome, sepsis, encephalopathy, viral infection, cranial nerve palsies
Postmarketing T cell malignancies including T-cell lymphoma, immune effector cell-associated enterocolitis and gastrointestinal perforation, infusion related reactions, JC virus progressive multifocal leukoencephalopathy
Most common (>=20%) CRS, pyrexia, any infection, febrile neutropenia, hypogammaglobulinemia, musculoskeletal pain, hypotension, infections-pathogen unspecified, fatigue, tachycardia, diarrhea, nausea, headache, encephalopathy, dyspnea, edema
Serious infections-pathogen unspecified, pneumonia, viral infections, encephalopathy, pyrexia, sepsis
Postmarketing Immune effector cell-associated neurotoxicity syndrome (ICANS), T cell malignancies
Pharmacology
CARVYKTI is a BCMA-directed, genetically modified autologous T cell immunotherapy that reprograms a patient's own T cells with a transgene encoding a CAR featuring two BCMA-targeting single-domain antibodies, a 4-1BB co-stimulatory domain, and a CD3-zeta signaling domain; upon binding to BCMA-expressing cells, the CAR promotes T cell activation, expansion, and elimination of target cells.
ABECMA is a BCMA-directed CAR-positive T cell therapy; the CAR construct uses an anti-BCMA scFv-targeting domain linked to CD3-zeta and 4-1BB intracellular signaling domains, resulting in CAR-positive T cell proliferation, cytokine secretion, and cytolytic killing of BCMA-expressing plasma cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Carvykti
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
Abecma
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Carvykti
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Abecma
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Carvykti
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Abecma
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableLeukemia & Lymphoma Society (LLS): Myeloma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCell Therapy 360 Patient Assistance Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CarvyktiView full Carvykti profile
AbecmaView full Abecma profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.